Tumors of the urinary system often manifest themselves late with symptoms, but are much more treatable in the early stages. Therefore, attempts are made to detect tumors at the earliest possible stages through early detection and screening examinations in at-risk patients.
Urine Dipsticks and Blood Detection – An Initial but Nonspecific Indicator
As part of screening examinations, urine tests are often carried out using conventional urine test strips. These allow, among other things, the detection of blood. However, this is very non-specific, as it is usually not caused by tumors, but by infections in the urinary tract. Exercise or menstruation in women can also lead to blood admixtures in the urine.
The actual tumor risk associated with hematuria depends critically on the type of blood presence: In purely microscopic microhematuria, the risk ranges from less than one to approximately three percent, depending on age. In visible macrohematuria, it can be significantly higher—particularly in older patients. Therefore, any unexplained blood in the urine must be medically evaluated.
Specific Urine Tests for Tumor-Associated Proteins
Screening procedures for tumors of the urinary system include urine tests that detect proteins that are produced more in the case of cancer. These include NMP22 BladderChek, UBC-Rapid, and BTAstat.
NMP22 proteins are associated with tumor cells of the urogenital tract and are present in higher concentrations in these cells than in healthy cells. When the cells die, NMP22 is excreted in the urine and can be detected using a specialized test. The test is considered relatively specific but has limited sensitivity—a negative test result does not reliably rule out a tumor.
UBC-Rapid also detects tumor-specific proteins, specifically fragments of cytokeratins 8 and 18, which may indicate the presence of a tumor in the urinary tract. In current comparative studies, the test achieves a sensitivity of approximately 84% for high-grade bladder tumors, exceeding that of conventional urine cytology.
BTAstat is a test that can detect bladder tumor antigen in urine using monoclonal antibodies. It also demonstrates good sensitivity for high-grade tumors, but its diagnostic value is compromised by infections, blood contamination, or recent procedures.
Newer Molecular Tests Are Gaining Importance
In addition to conventional rapid tests, molecular biological methods have established a firm place in urological diagnostics and follow-up care in recent years. These include the UroVysion FISH test, which detects genetic alterations in chromosomes 3, 7, 9, and 17, as well as mRNA-based tests such as Xpert Bladder Cancer Monitor or CxBladder. These methods achieve greater diagnostic value than conventional protein tests, particularly in the follow-up care of patients with known bladder cancer, and are evaluated accordingly in current European guidelines.
Limitations of Screening Tests
These tests are only recommended for screening at-risk patients and for follow-up care of patients with bladder cancer. They are not sufficient for diagnosing a bladder tumor—cystoscopy remains necessary for this purpose and is still considered the gold standard of diagnostics in current German and European guidelines.
Widespread screening of asymptomatic individuals is expressly not recommended according to the current S3 guideline on bladder carcinoma (as of April 2025). The appropriate use of the aforementioned tests is limited to defined risk groups and follow-up care—never for diagnosis alone.
Sources
AWMF – S3 Guideline “Early Detection, Diagnosis, Treatment and Follow-up of Bladder Carcinoma” (032-038OL, April 2025): register.awmf.org
Guideline Program Oncology – Bladder Carcinoma: leitlinienprogramm-onkologie.de
European Association of Urology (EAU) – Guidelines on Non-Muscle-Invasive Bladder Cancer: uroweb.org
German Cancer Research Center (DKFZ) – Cancer Information Service Bladder Cancer: krebsinformationsdienst.de
Multicenter Comparative Study of Urine-Based Rapid Tests (2023), PubMed: pubmed.ncbi.nlm.nih.gov
The content of this article is for general information purposes only and has been prepared with the utmost care based on recognized medical sources. It does not constitute a healing claim, diagnosis, or therapy recommendation and in no case replaces a personal consultation with a qualified physician. In case of doubt or persistent symptoms, please seek medical advice immediately. Medipee assumes no liability for decisions you make based on the information provided here.
